Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genzyme, Osiris, U.S. Department of Defense other news

The U.S. Department of Defense awarded Osiris a $224.7 million contract to develop and stockpile Prochymal to treat acute radiation syndrome (ARS). The agency

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE